Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01054144 · OUTCOME

Single Agent - Median Progressive Free Survival (PFS)

Study of Single Agent Lenalidomide in Older Adults With Newly Diagnosed Multiple Myeloma · Source last updated 2021-10-13

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
95% Confidence Interval
Time frame
First measure at 8 weeks

What was measured

The progression free survival of patients treated with single agent lenalidomide

Groups in this outcome

Single Agent

Participants who were treated with single agent lenalidomide only

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Single Agent18

Reported measurements

Source class 1
Values in months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Single Agent29Not reported25.773.5Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        25.7
        upper Limit
        73.5
        value
        29
denoms
  1. counts
    1. group Id
      OG000
      value
      18
    units
    Participants
description
The progression free survival of patients treated with single agent lenalidomide
dispersion Type
95% Confidence Interval
groups
  1. description
    Participants who were treated with single agent lenalidomide only
    id
    OG000
    title
    Single Agent
param Type
MEDIAN
reporting Status
POSTED
time Frame
First measure at 8 weeks
title
Single Agent - Median Progressive Free Survival (PFS)
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice